Last reviewed · How we verify
Hydroxyethylstarch 6% 130/0.4
Hydroxyethylstarch (HES) 6% 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space.
Hydroxyethylstarch (HES) 6% 130/0.4 is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and maintaining fluid in the vascular space. Used for Acute hypovolemia and restoration of circulating blood volume in perioperative and critical care settings.
At a glance
| Generic name | Hydroxyethylstarch 6% 130/0.4 |
|---|---|
| Also known as | Any volume therapy has been recorded |
| Sponsor | Medical University of Vienna |
| Drug class | Synthetic colloid plasma volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
HES is a starch-based plasma volume expander composed of glucose polymers with a molecular weight of 130 kDa and degree of substitution of 0.4. It functions as a colloid, drawing and retaining fluid within the intravascular compartment to restore circulating blood volume and improve tissue perfusion during hypovolemia. The 0.4 substitution ratio indicates moderate hydroxyethylation, which affects the molecule's persistence in circulation and metabolic degradation.
Approved indications
- Acute hypovolemia and restoration of circulating blood volume in perioperative and critical care settings
Common side effects
- Acute kidney injury
- Coagulopathy / increased bleeding
- Hyperchloremic acidosis
- Anaphylaxis
Key clinical trials
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Cardiac Output in Preeclamptic (NA)
- Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery (PHASE4)
- The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning (NA)
- 6% Hydroxyethyl Starch (130/0.4) Coload for Postspinal Anesthesia Hypotension (NA)
- Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine (NA)
- Endothelial Function After Cardiac Surgery (NA)
- Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxyethylstarch 6% 130/0.4 CI brief — competitive landscape report
- Hydroxyethylstarch 6% 130/0.4 updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI